MCID: CHR283
MIFTS: 52

Chronic Inflammatory Demyelinating Polyneuropathy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyneuropathy:

Name: Chronic Inflammatory Demyelinating Polyneuropathy 38 76 53 54 59
Chronic Inflammatory Demyelinating Polyradiculoneuropathy 53 59
Cidp 53 59
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 73

Characteristics:

Orphanet epidemiological data:

59
chronic inflammatory demyelinating polyneuropathy
Inheritance: Not applicable; Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA2932
UMLS via Orphanet 74 C0393819
ICD10 via Orphanet 34 G61.8

Summaries for Chronic Inflammatory Demyelinating Polyneuropathy

NIH Rare Diseases : 53 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder that causes progressive weakness and impaired sensory function in the legs and arms. Symptoms often include tingling or numbness (first in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes, fatigue, and abnormal sensations. CIDP is thought to be caused by the immune system mistakenly attacking and damaging the myelin sheath (protective cover of nerve fibers) of the peripheral nerves. CIDP is closely related to Guillain-Barre syndrome (GBS) and is considered the "chronic counterpart" of GBS. Treatment may include corticosteroids, immunosuppressant drugs, plasma exchange, physical therapy, and/or intravenous immunoglobulin (IVIG) therapy. Left untreated, 30% of people with CIDP will progress to wheelchair dependence.

MalaCards based summary : Chronic Inflammatory Demyelinating Polyneuropathy, also known as chronic inflammatory demyelinating polyradiculoneuropathy, is related to demyelinating polyneuropathy and chronic inflammatory demyelinating polyradiculoneuropathy. An important gene associated with Chronic Inflammatory Demyelinating Polyneuropathy is HP (Haptoglobin), and among its related pathways/superpathways are Cell adhesion molecules (CAMs) and L1CAM interactions. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and skin, and related phenotypes are areflexia and unsteady gait

NINDS : 54 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. The disorder, which is sometimes called chronic relapsing polyneuropathy, is caused by damage to the myelin sheath (the fatty covering that wraps around and protects nerve fibers) of the peripheral nerves. Although it can occur at any age and in both genders, CIDP is more common in young adults, and in men more so than women. It often presents with symptoms that include tingling or numbness (beginning in the toes and fingers), weakness of the arms and legs, loss of deep tendon reflexes (areflexia), fatigue, and abnormal sensations. CIDP is closely related to Guillain-Barre syndrome and it is considered the chronic counterpart of that acute disease.

Wikipedia : 76 Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory... more...

Related Diseases for Chronic Inflammatory Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Related Disease Score Top Affiliating Genes
1 demyelinating polyneuropathy 28.5 AIF1 CNTN2 HP NFASC TTR
2 chronic inflammatory demyelinating polyradiculoneuropathy 12.6
3 lewis-sumner syndrome 11.5
4 polyneuropathy 11.3
5 neuropathy 10.6
6 diabetes mellitus 10.3
7 hepatitis 10.3
8 myasthenia gravis 10.3
9 charcot-marie-tooth disease 10.3
10 tooth disease 10.3
11 myasthenia gravis congenital 10.3
12 multiple sclerosis 10.2
13 poems syndrome 10.2
14 melanoma 10.2
15 hepatitis b 10.2
16 multifocal motor neuropathy 10.2
17 lymphoma 10.2
18 lupus erythematosus 10.2
19 systemic lupus erythematosus 10.1
20 glomerulonephritis 10.1
21 respiratory failure 10.1
22 carpal tunnel syndrome 10.0
23 focal segmental glomerulosclerosis 1 10.0
24 mononeuropathy of the median nerve, mild 10.0
25 membranous nephropathy 10.0
26 arthritis 10.0
27 crohn's disease 10.0
28 diabetic neuropathy 10.0
29 focal segmental glomerulosclerosis 10.0
30 scoliosis 10.0
31 abducens nerve disease 10.0
32 diabetic polyneuropathy 10.0
33 guillain-barre syndrome 10.0
34 mononeuritis multiplex 10.0
35 hepatitis c 10.0
36 sensory peripheral neuropathy 10.0
37 cervicitis 10.0
38 myopathy 10.0
39 neuronitis 10.0
40 psoriasis 10.0
41 intracranial hypertension 10.0
42 type i 10.0
43 amyloid neuropathy 10.0
44 endotheliitis 10.0
45 amyotrophic lateral sclerosis 1 9.9
46 biliary cirrhosis, primary, 1 9.9
47 hepatocellular carcinoma 9.9
48 creutzfeldt-jakob disease 9.9
49 rheumatoid arthritis 9.9
50 trigeminal neuralgia 9.9

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyneuropathy

Human phenotypes related to Chronic Inflammatory Demyelinating Polyneuropathy:

59 32 (show all 17)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 areflexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001284
2 unsteady gait 59 32 hallmark (90%) Very frequent (99-80%) HP:0002317
3 paresthesia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003401
4 segmental peripheral demyelination/remyelination 59 32 hallmark (90%) Very frequent (99-80%) HP:0003481
5 sensory ataxia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010871
6 motor conduction block 59 32 hallmark (90%) Very frequent (99-80%) HP:0012078
7 fatiguable weakness of proximal limb muscles 59 32 hallmark (90%) Very frequent (99-80%) HP:0030200
8 difficulty walking 59 32 frequent (33%) Frequent (79-30%) HP:0002355
9 falls 59 32 frequent (33%) Frequent (79-30%) HP:0002527
10 difficulty climbing stairs 59 32 frequent (33%) Frequent (79-30%) HP:0003551
11 hand muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0030237
12 spontaneous pain sensation 59 32 occasional (7.5%) Occasional (29-5%) HP:0010833
13 decreased nerve conduction velocity 59 Very frequent (99-80%)
14 sensory impairment 59 Very frequent (99-80%)
15 peripheral neuropathy 59 Very frequent (99-80%)
16 peripheral demyelination 59 Very frequent (99-80%)
17 abnormal nerve conduction velocity 59 Very frequent (99-80%)

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
9 tannic acid Approved, Nutraceutical Phase 3
10 Fingolimod Hydrochloride Phase 3
11 Immunosuppressive Agents Phase 3,Phase 2
12 Immunoglobulin G Phase 3,Not Applicable
13 Anti-Inflammatory Agents Phase 3
14 Antineoplastic Agents, Hormonal Phase 3
15 glucocorticoids Phase 3
16 Hormone Antagonists Phase 3,Phase 2
17 Hormones Phase 3,Phase 2
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
19 Pharmaceutical Solutions Phase 3,Phase 2
20
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22 Antioxidants Phase 2
23 Micronutrients Phase 2
24 Protective Agents Phase 2
25 Thioctic Acid Phase 2
26 Trace Elements Phase 2
27 Vitamin B Complex Phase 2
28 Vitamins Phase 2
29 Adjuvants, Immunologic Phase 2
30 Anti-Infective Agents Phase 2
31 Antiviral Agents Phase 2
32 Interferon-beta Phase 2
33 interferons Phase 2
34 Antirheumatic Agents Phase 2
35 Alpha-lipoic Acid Nutraceutical Phase 2
36 Folate Nutraceutical Phase 2
37 Vitamin B9 Nutraceutical Phase 2
38
Infliximab Approved 170277-31-3
39 Dermatologic Agents
40 Gastrointestinal Agents

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
5 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
6 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
10 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
12 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
15 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
16 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
17 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
18 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
19 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
21 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
22 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
23 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
24 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
25 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
26 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
27 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
28 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
29 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
30 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
31 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
32 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
33 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
34 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
35 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
36 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
37 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
38 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
39 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
40 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
41 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
42 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
43 Transcriptome Analysis of the Peripheral Blood in CIDP Active, not recruiting NCT02404298 Not Applicable IVIg
44 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890 Not Applicable
45 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyneuropathy

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Chronic Inflammatory Demyelinating Polyneuropathy:
Hematopoietic stem cells for treatment of chronic inflammatory demyelinating polyneuropathy
Embryonic/Adult Cultured Cells Related to Chronic Inflammatory Demyelinating Polyneuropathy:
Bone marrow-derived hematopoietic stem cells PMIDs: 17277794

Genetic Tests for Chronic Inflammatory Demyelinating Polyneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyneuropathy:

41
T Cells, Bone, Skin, Spinal Cord, Endothelial, B Cells, Thyroid

Publications for Chronic Inflammatory Demyelinating Polyneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyneuropathy:

(show top 50) (show all 569)
# Title Authors Year
1
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
2
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
3
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
4
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
5
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
6
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
7
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
8
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
9
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
10
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
11
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
12
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
13
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
14
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
15
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
16
High-resolution nerve ultrasound and magnetic resonance neurography as complementary neuroimaging tools for chronic inflammatory demyelinating polyneuropathy. ( 29552093 )
2018
17
Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance. ( 29867996 )
2018
18
Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? ( 29603302 )
2018
19
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
20
Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials. ( 29700616 )
2018
21
Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. ( 29541543 )
2018
22
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
23
Utility of Neurological Imaging in Sensory Variant of Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 28221307 )
2017
24
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE). ( 28894082 )
2017
25
Neuromuscular ultrasound findings in distal acquired demyelinating symmetric variant of chronic inflammatory demyelinating polyneuropathy. ( 28667663 )
2017
26
ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. ( 28796305 )
2017
27
Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. ( 28480635 )
2017
28
Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patientA -A a case report. ( 29073825 )
2017
29
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. ( 28768822 )
2017
30
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy. ( 28855494 )
2017
31
Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report. ( 28984777 )
2017
32
Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. ( 28108521 )
2017
33
The Prevalence and Severity of Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyneuropathy. ( 28904461 )
2017
34
Electrodiagnostic misdiagnosis of chronic inflammatory demyelinating polyneuropathy: What are the problems? and how to right the wrongs. ( 29193155 )
2017
35
Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. ( 28575198 )
2017
36
Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy. ( 29075571 )
2017
37
Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series. ( 29143254 )
2017
38
Chronic inflammatory demyelinating polyneuropathy. ( 28763304 )
2017
39
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. ( 28073817 )
2017
40
Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. ( 29175895 )
2017
41
Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic Accuracy and Correlation With Electrophysiology. ( 28574858 )
2017
42
Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. ( 29043889 )
2017
43
Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins. ( 28747620 )
2017
44
Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. ( 29194677 )
2017
45
Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. ( 28085193 )
2017
46
Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. ( 29053880 )
2017
47
Lumbar plexus in patients with chronic inflammatory demyelinating polyneuropathy: Evaluation with 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). ( 28668438 )
2017
48
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ( 28000311 )
2017
49
A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. ( 28485075 )
2017
50
Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. ( 28345260 )
2017

Variations for Chronic Inflammatory Demyelinating Polyneuropathy

Expression for Chronic Inflammatory Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyneuropathy

Pathways related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.42 CNTN2 NFASC
2
Show member pathways
11.25 CNTN2 NFASC
3 11.03 AIF1 GDNF
4 10.19 CNTN2 GDNF

GO Terms for Chronic Inflammatory Demyelinating Polyneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.96 CNTN2 NFASC
2 node of Ranvier GO:0033268 8.62 CNTN2 NFASC

Biological processes related to Chronic Inflammatory Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neutrophil degranulation GO:0043312 9.43 HP NFASC TTR
2 neuron projection development GO:0031175 9.32 CNTN2 GDNF
3 peripheral nervous system development GO:0007422 9.16 GDNF NFASC
4 axon guidance GO:0007411 9.13 CNTN2 GDNF NFASC
5 protein localization to juxtaparanode region of axon GO:0071205 8.62 CNTN2 NFASC

Sources for Chronic Inflammatory Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....